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Abstract: In the present study, a novel poly-lactic glycolic acid (PLGA)-based microparticle 
formulation of perillyl alcohol (POH) was prepared and characterized. Further, its efficacy was 
evaluated against di-methyl benzo anthracene-induced skin papilloma in Swiss albino mice. 
The characterization studies showed that POH-bearing PLGA microparticles were of the size 
768 ± 215 nm with a ζ-potential value of −7.56 ± 0.88 mV . The entrapment efficiency of the 
active drug in particles was 42.4% ± 3.5%. POH-bearing PLGA microparticles were stable 
and released entrapped drug gradually over an extended time period. The in vitro efficacy of 
POH-bearing PLGA microparticles was evaluated by examining their differential cytotoxicity 
and assessing their ability to inhibit epidermoid carcinoma cell line (A253). The POH-based 
microparticles when administered to tumor-bearing animals caused greater tumor regression 
and increased survival rate (∼80%) as compared with the group receiving free form of POH 
(survival rate 40%). The superiority of POH-PLGA microparticles over free form of POH was 
further evident from their ability to modulate apoptosis-regulating factors.
Keywords: poly-lactic glycolic acid, epidermoid cancer cells, skin papilloma, anticancer 
efficacy
Introduction
Cytotoxicity and other related side effects are the most serious problems associated 
with the currently available anticancer drugs. Other limitations include widespread 
systemic distribution and rapid elimination of the administered anticancer drugs from 
the host body. A worldwide search therefore continues for anticancer drugs that are 
more potent, less toxic, and manifest minimum untoward effects to the host. Several 
plant derived compounds have been reported to possess strong anticancer properties and 
have been shown to delay, inhibit, or reverse cancerous growth in an effective   manner. 
For example, perillyl alcohol (POH), a plant-based compound, has been reported to 
possess strong anti-cytotoxic properties against several types of cancer including those 
of breast, pancreatic, and liver.1–3 POH is a monoterpene and constituent of essential 
oils from a number of plants; namely, perilla (Perilla frutescens), lavendin, peppermint, 
ginger grass, savin, caraway, and celery seeds.4
Before translating the suitability of a novel compound like POH as a potential 
anticancer agent in the clinical setting, it is desirable to address some of the associated 
issues like that of its solubility, palatability, and sustained/controlled release in systemic 
circulation. This requires designing of a suitable drug-delivery system that can release 
the drug gradually over a long period of time and, in turn, facilitate its uptake by cancer 
cells and thereby helps in increasing the efficacy of the entrapped drug. Polymeric International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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microparticles offer a promising technology in this regard. 
Encapsulation of drugs in the core of microparticles have been 
shown not only to protect them from the external environment 
enroute, but also help in increasing their plasma half-lives 
in systemic circulation thereby facilitating the attainment of 
optimum drug availability at the desired target.5–7
To develop promising and effective formulations of 
anticancer compounds, various polymeric matrices have 
been investigated and their efficacies worked out.5–10 Drug-
delivery systems, such as nanoparticle-,5 microemulsion-,6 
nanoemulsion-,7 and liposome-based delivery systems,8–10 
have been shown to enhance the efficacy of various 
compounds on systemic as well as topical applications. 
Among various drug-carrier systems, poly-lactic glycolic 
acid (PLGA) matrices have been reported to be nontoxic, 
biodegradable, and shown to release the entrapped drug 
gradually over a long duration.11
In the present study, POH-bearing PLGA microparticles 
were prepared and their efficacy against the skin epidermoid 
cancer cell line (A253) was evaluated. In addition, potential 
of POH-bearing PLGA microparticles was evaluated in 
treatment of di-methyl benzo anthracene (DMBA)-induced 
tumors in Swiss albino mice.
Materials and methods
All reagents used in the study were of highest purity 
available. PLGA, poly vinyl alcohol (PVA), and POH were 
purchased from Sigma Chemical Company (St Louis, MO). 
Dichloromethane (DCM) was of analytical grade of purity 
and procured locally. Anti-p53 mutant, anti-p53 wild-type 
(wt), anti-p21/waf1, anti-tubulin and anti-β-actin antibodies 
were purchased from BD Biosciences (San Diego, CA).
Preparation of POH-loaded PLGA 
microparticles
Microparticles used in the present study were prepared by 
oil-in-water-based emulsion solvent evaporation technique 
using the published protocol as standardized in our 
laboratory.12,13 Briefly, a known quantity of POH (30 mg) 
was dissolved in minimum volume of methanol, mixed with 
PLGA solution (190 mg PLGA dissolved in 1.0 mL DCM), 
and sonicated in a bath-type sonicator to form the primary 
emulsion. The primary emulsion was mixed with 100 mL of 
10% PVA (w/v) and homogenized using a Silverson L4RT 
homogenizer (Silverson Machines, East Longmeadow, MA). 
The resulting oil-in-water emulsion was stirred at 25°C for 
18 hours to allow solvent evaporation and formation of 
POH-entrapped microparticles. The microparticles were 
centrifuged and thoroughly washed with phosphate buffered 
saline (PBS) (0.15 M NaCl containing 20 mM sodium 
phosphate, pH 7.4) to remove surface adsorbed drug. The 
microformulation was lyophilized and finally stored at 4°C 
until further use.
Entrapment efficiency of POH  
in microparticles
Entrapment of POH in microparticles was assessed by 
dissolving an aliquot of the microparticles in 0.1 N NaOH 
followed by analysis of POH content by high-performance 
liquid chromatography (HPLC) following the published 
procedure.14 Briefly, 10 mg freeze-dried microparticles 
were dissolved in 1.0 mL of 0.1 N NaOH. The solution 
was vortexed for 10 minutes followed by centrifugation 
for 5 minutes at 9168 × g at 25°C. An aliquot (100 µL) of 
supernatant was mixed with 900 µL methanol. The suitable 
aliquots, of the resultant homogenate solution, were analyzed 
by reversed phase HPLC using a Symmetry® C-18 column 
(3.9 mm × 150 mm). The solvent system used was isocratic 
methanol-water (72:28, v/v). Entrapment of POH was 
calculated with the help of calibration curve using the pure 
drug plotted at 220 nm. The percentage entrapment efficiency 
(% EE) was calculated with the following formula.
% EE = (amount of POH entrapped)
  /(total amount of POH used in the beginning) × 100.
scanning electron microscopy  
of the microparticles
Scanning electron microscopy (SEM) was performed to char-
acterize the size and surface morphology of POH-loaded 
microparticles using scanning electron microscope (Zeiss 
EVO 40; Carl Zeiss SMT AG, Oberkochen, Germany). The 
lyophilized preparation of POH-loaded microparticles was 
suspended in 20 mM PBS pH 7.4, and a drop of the formula-
tion was mounted on clear glass stub, air dried, and coated 
with gold-palladium alloy using a sputter coater. An accel-
erating voltage of 20.00 kV was used for imaging.
Determination of ζ-potential
ζ-potential of the PLGA microparticles was determined using 
DTS software (Malvern Instruments Ltd, Worcestershire, 
UK) based on M3-PALS technology. The formulation was 
lyophilized in a 2.0 mL microfuge tube, and the samples 
were reconstituted in 20 mM phosphate buffer, pH 7.4. This 
dispersion was then rapidly dispensed to a electrophoresis 
cell to measure the electrophoretic mobility, and ζ-potential International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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values were calculated. The experiment was repeated three 
times, and the average ζ-potential with standard deviation 
was calculated.
In vitro release kinetics of active POh 
from PLgA microparticles
To assess the release kinetics of POH from PLGA micropar-
ticles, multiple weighed aliquots of the microparticles were 
dispensed in separate microvials. To each vial, 1.0 mL of 
20 mM sterile PBS was added, followed by incubation at 
37°C. Aliquots (100 µL) of supernatant were removed after 
centrifugation at 9168 × g for 10 minutes and analyzed for 
the POH content.
Toxicity tests for POH-bearing PLGA 
microformulation
A new formulation of a given drug molecule has to be 
tested for any inherent toxicity before being examined for its 
efficacy. To settle this issue, toxicity of the in-house prepared 
formulation was tested both in vitro and in vivo. Preliminary 
acute drug toxicity was based on in vitro erythrocyte lysis 
test, wherein hemoglobin, released as a result of membrane 
leakage or disruption caused by exposure to low doses of 
the drug, is measured.15 Briefly, fresh blood was obtained 
from a healthy rabbit and collected in anticoagulant solution 
(ethylenediaminetetraacetic acid), followed by centrifugation 
at 1000 × g for 10 minutes at 4°C. Buffy coat as well as 
plasma was discarded. The washed erythrocytes were diluted 
with isotonic buffer (20 mM PBS), and 50% hematocrit was 
prepared. To study the extent of hemolysis, the suspension 
of red blood cells (RBCs) was incubated with 1.0 mL of free 
form as well as POH encapsulated in PLGA microparticles 
(10 mg/mL) at 37°C for 1 hour. Free POH was dissolved in 
50 µL of dimethyl sulfoxide (DMSO), and finally volume was 
made up to 1.0 mL with PBS (final 5% DMSO). After 1 hour, the 
reaction mixture was centrifuged at 1500 × g, and supernatant 
was collected and analyzed by ultraviolet-visible spectroscopy 
(λmax = 576 nm) for released hemoglobin. The percentage 
hemolysis was determined by the following equation:
  [(AbsT − AbsC)/Abs100% − AbsC)] × 100,
where AbsT is the absorbance of the supernatant from 
samples incubated with the drugs, AbsC is the absorbance 
of the supernatant from controls (PBS), and Abs100% is 
the absorbance of the supernatant of controls incubated in 
the presence of 1% Triton® X-100, which causes complete 
lysis of RBCs (total hemolysis).
Hepatic and renal toxicities were monitored by applying 
multidose regimen (total seven doses, at alternate days) to 
determine biochemical profiles of serum creatinine and 
alkaline phosphatase (ALP). The blood was collected by 
retro-orbital puncture from the mice of different groups after 
the last administered dosage. The blood was allowed to clot 
at room temperature, and serum was separated for investiga-
tion of creatinine and ALP as per respective guide provided 
by the manufacturer.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay
Epidermoid carcinoma cell line A253 (ATCC HTB-41™) 
was purchased from ATCC (Manassas, VA) and maintained in 
Roswell Park Memorial Institute (RPMI) 1640 culture medium 
supplemented with 10% heat-inactivated fetal calf serum. To 
perform MTT assay, 5 × 104 cells were transferred to each well 
of a 96-well plate. The plate was incubated for 24 hours, and 
then increasing concentrations (0–60 µg/mL) of POH were 
added to each well, three wells received medium only with 
no POH and served as control. The plate was incubated for 
72 hours, and cell proliferation was measured by adding 20 µL 
MTT dye (5 mg/mL in PBS) per well. After further incubation 
for another 4 hours at 37°C in a humidified chamber with 5% 
CO2, the formazan crystals formed due to reduction of dye 
by viable cells in each well were dissolved in 150 µL DMSO, 
and optical density (OD) was read at 620 nm in a SpectraMax 
M2 plate reader (Molecular Devices, Sunnyvale, CA).
Effect of POH-PLGA-microparticles  
in induction of apoptosis in the human 
epidermoid cancer cell line
To examine the in vitro inhibitory effect of POH-bearing 
PLGA microparticles, the microformulation as well as free 
form drug was incubated with A253 cells (1 × 108 cells) for 
12 and 24 hours. After incubation, the cells were scraped, 
centrifuged, and washed with RPMI medium and lysed with 
TNN lysis buffer. The lysate was subjected to 12% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, and 
gels were electroblotted on polyvinylidine fluoride (PVDF) 
membrane following published protocol.16
Animals
Female Swiss albino mice of weight 20 ± 2 g were obtained 
from the institute’s animal house facility. The animals were 
housed in poly propylene cages on wood powder bedding 
in an air-conditioned ambience. Animals were quarantined International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
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on equal light/dark cycles (12/12 hour) and were kept 
on a pellet diet (Ashirwad, Chandigarh, India) and water 
ad libitum.   Animals were examined for their mortality and 
morbidity prior to commencement of the study, and only 
healthy animals were included in the experiments. The 
techniques used for administration of various formulations 
as well as sacrifice of the animals were strictly performed 
following mandates approved by the animal ethics committee 
(Committee for the Purpose of Control and Supervision of 
Experiments on Animals, Government of India).
Treatments
Animals in the resting phase of hair cycle were used in the 
study. The interscapular regions (over an area of 2 cm2) of 
the experimental animals were shaven using non lubricated 
electric clippers. The mouse skin tumors were induced by using 
DMBA as carcinogen following the procedure standardized 
in our laboratory.10 The skin of the shaven dorsal portion of 
the mice was exposed to DMBA (52 µg in 200 µL acetone) 
that was applied topically three times a week for 12 weeks. 
Animals were routinely examined for gross morphological 
changes on skin and development of tumors. It has been 
reported that POH at 10 mM concentration does not cause 
toxicity in a mice model.17 This fact was kept in mind when 
selecting specific dosage regimens of various cream-based 
POH formulations. The formulations of POH were applied 
daily with cream base for a period of 7 days after induction of 
papilloma, with a dose of 10 mM POH in 500 µL cream base 
per animal. Animals were observed for 1 month to examine the 
effect of various formulations. The animals were divided into 
the following groups; each consisting of 15 animals: Group I, 
untreated control (DMBA applied, followed by treatment 
with cream base only); Group II, sham PLGA microparticles; 
Group III, control (healthy animals); Group IV , POH (free 
form); Group V , POH-bearing PLGA microparticles.
Tumor measurement
Tumor measurement was carried out after 1 month of last 
dosage application of various POH-based formulations. 
The diameters of the tumors were measured using a Vernier 
Caliper, and the tumor volume was determined using the 
following formula:
  V = D × d2 × π/6,
where V = tumor volume, D = biggest dimension, and 
d = smallest dimension.
histopathological studies
Animals were sacrificed and their excised papillomas were 
immersion fixed in 10% formalin. Next, the tissue blocks of 
3 × 6 × 5 mm3 dimensions were processed for paraffin embed-
ding. Thick sections (10 micrometer) were cut with rotary 
microtome and stained with H and E stain. Observations 
were made under light microscope (Olympus-BX 40-Japan), 
representative photomicrographs with final magnification of 
X100 were used for comparative study.
Preparation of nuclear fraction
The skin/tumor tissues were removed from experimental mice 
using sharp scalpel blades. The tissue samples were placed 
on ice, and fat was scraped off before further processing. 
The samples were homogenized in the presence of protease 
inhibitor cocktail, and the nuclear fraction was prepared 
according to the method published elsewhere.18
Western blotting
The tissue homogenate was analyzed for the presence of 
various apoptotic factors by Western blotting.16 Briefly, the 
protein content of the homogenate was determined by Lowry 
et al method using bovine serum albumin as a standard.19 
The homogenate (30 µg/well) was subjected to PAGE under 
nondenaturing conditions. The gels were electroblotted onto 
PVDF membranes, blocked overnight with 5% non-fat dry 
milk and probed with appropriate antibodies at the dilutions 
recommended by the suppliers. To quantify equal loading, 
membranes were re-probed with α-tubulin antibody to deter-
mine housekeeping protein tubulin.
statistical analysis
One-way analysis of variance was used for comparing the 
mean values of tumor volume between various groups after 
ascertaining the homogeneity of variance between treatments. 
Post-hoc analysis for comparing the two groups was done 
using the least statistical difference technique. The Kaplan-
Meier analysis was used to determine survival of tumor-free 
animals, and differences among various experimental groups 
were analyzed by log-rank test.
Results
Entrapment efficiency, size, and 
ζ-potential of PLGA microparticles
Various PLGA-based microparticle formulations have been 
widely used for the delivery of antibiotics as well as antican-
cer drugs to accomplish sustained release of the entrapped International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
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drugs.14,20 The in-house developed PLGA microparticles 
had entrapment efficiency of 42.4 ± 3.5, and size was 
768 ± 215 nm, as revealed by SEM and Nanophox (Sympatec 
GmbH, Clausthal-Zellerfeld, Germany) size analyzer 
(Figure 1A and B). As ζ-potential acquired by a small sized 
particle regulates its half-life in vitro as well as in vivo, it was 
considered important to determine ζ-potential of the in-house 
prepared microparticles. The POH-PLGA microparticles used 
in the present study had a ζ-potential of −7.6 ± 0.8 mV .
In vitro release kinetics of POH-loaded 
PLgA microparticles
In vitro release kinetics of POH-loaded PLGA micropar-
ticles was studied at 37°C in PBS, pH 7.4. POH-PLGA 
microparticles showed sustained release, with only 12% of 
the entrapped drug leaking out in the initial 18 hours. In the 
next 12 hours, around 17% of  the total drug was released. 
PLGA microparticles showed an initial burst release pattern 
followed by sustained release kinetics for extended time 
period. In the present study, PLGA microparticles were 
found releasing 22% in the initial 72 hours with an overall 
total 30% release in 168 hours (Figure 1C).
In vitro and in vivo toxicity of POH-based 
PLgA microparticle formulation
Before determining the efficacy of any formulation, it is 
desirable to assess its intrinsic toxicity. With this aim, POH-
bearing PLGA microparticle (in-house prepared) toxicity 
was evaluated, and it was found that POH-bearing PLGA 
microparticles had induced relatively less percent RBC 
lysis than free form of the drug (Figure 2). Sham PLGA also 
induced very negligible lysis.
In another set of experiments, animals treated with 
multiple dosages of POH-bearing PLGA microparticles were 
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Figure 1 (A) Scanning electron microscopy image of POH-loaded PLGA microparticles. (B) Corresponding particle analyzer data as obtained by Nanophox (Sympatec 
GmbH, Clausthal-Zellerfeld, Germany) particle size analyzer. (C) In vitro release kinetics from PLGA microparticles. Release kinetics of POH-PLGA microparticle formulation 
demonstrates ∼30% release of POH from the copolymer at 168 hours, when formulation was dispersed in 20 mM phosphate buffer, pH 7.4 at 37°c. 
Note: Data are means ± standard deviations of three independent experimental values.
Abbreviations: PLGA, poly-lactic glycolic acid; POH, perillyl alcohol; EHT, extra high tension; WD, working distance.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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analyzed for liver as well as renal function test parameters to 
evaluate in vivo toxicity. As shown in Table 1, POH-bearing 
PLGA microparticles had comparatively low levels of ALP 
and creatinine than the free form of the drug. The results 
established that POH-bearing PLGA microparticles did not 
have any in vitro and in vivo toxicity and are safe to use.
Cytotoxic effect of POH-bearing PLGA 
microparticles
The cytotoxic effect of POH formulations against epidermoid 
cancer cells was studied using MTT assay as shown in 
Figure 3. The data shows that the cytotoxic effect of POH 
was significant on epidermoid cancer cells at a concentra-
tion of 25 µg/mL and resulted in killing of about 50% of the 
cell population.
Nanoparticles are endocytosed by cells faster,20 enabling 
high payload of drug molecules, and exhibit more cytotoxic 
effect. With this hypothesis, the differential cytotoxicity of 
free and PLGA microparticle-encapsulated POH at its half-
maximal inhibitory concentration (IC50) was investigated. As 
shown in Figure 4, free POH caused 50% cell death, whereas 
it increased to ∼65% in the POH-PLGA microparticle-treated 
group in 48 hours incubation (POH-PLGA-microparticle 
versus free POH; P , 0.001). In addition, the time-dependent 
efficacy of POH-bearing microparticles on epidermoid 
cancer cell system was examined. As shown in Figure 5A, 
POH-PLGA microparticles enhanced the expression of p21/
waf1 and bax at 12 hours post-incubation, whereas POH 
in free form was not very effective. Similarly, 24 hours 
post-incubation, the expression of p21/waf1 in cells treated 
with POH-PLGA microparticles increased further, while the 
free form drug was not found to be effective (Figure 5B). 
The results clearly suggest that microparticle encapsulated 
POH is delivered efficiently to the cancer cells and can easily 
modulate various apoptotic factors and eventually results in 
apoptosis of the cancer cells.
Effect of POH-PLGA microparticles  
on regression of tumors and survival  
of animals
After establishing anticancer efficacy of inhouse-prepared 
microparticles against cancer cells in vitro, the present study 
was extended in vivo using a mouse model of skin carcinoma. 
For this purpose, regression in the volume of DMBA-induced 
tumors was measured after treatment with various POH 
formulations. As shown in Figure 6, the percent regression 
was much higher in the POH-PLGA microparticle-treated 
group as compared with those receiving the free form of the 
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Figure 2 erythrocyte lysis test: In vitro toxicity was measured by erythrocyte lysis caused by different POh formulations.
Notes: hemolysis test was performed as described in the Materials and methods section. Data represented here are means of three different experiments ± standard 
deviations.
Abbreviations: DMSO, dimethyl sulfoxide; PLGA, poly-lactic glycolic acid; POH, perillyl alcohol.
Table 1 concentrations of creatinine and ALP in plasma of animals 
treated with POH-bearing PLGA microparticle formulation
Groups Creatinine (mg %) ALP (IU/L)
control 0.32 ± 0.052 32.46 ± 2.12
sham PLgA microparticles 0.28 ± 0.034 36.88 ± 3.41
POH (free form) 0.35 ± 0.038 44.28 ± 2.32
POH-PLGA microparticles 0.31 ± 0.011 34.25 ± 2.14
Abbreviations: ALP, alkaline phosphatase; PLGA, poly-lactic glycolic acid; POH, 
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drug (P value ,0.001; POH-PLGA-microparticle versus 
free POH). The treatment with microparticle-based POH 
formulation resulted in 80% tumor regression, while the 
free form of drug was able to regress tumor by 65% only. 
The sham microparticles were devoid of any significant 
anticancer activity.
Next, the efficacy of POH-PLGA microparticles was 
assessed in terms of the survival of treated animals.   Survival 
graph shows the augmentation of anticancer efficacy of 
PLGA-encapsulated POH microparticles as well as free form 
POH against DMBA-induced tumorogenesis at different time 
points. POH-encapsulated PLGA microparticles showed 
80% survival, whereas the group receiving free form of POH 
resulted in only 40% survival in 13 weeks (POH-PLGA 
microparticles versus free POH; P , 0.05). None of the 
animals survived beyond 12 weeks in the control group that 
was treated with cream base only (P , 0.01) (Figure 7).
histopathological analysis
For histopathological studies, skin tissue samples were 
isolated from animals of various groups and analyzed 
following the protocol described in Materials and methods. 
  Histopathological studies of tumors identified papillomas 
in various groups. However, the relative frequency of the 
individual tumor types differed among animals receiving 
different treatments. In the skin of healthy animals, there 
were only a few cell layers thick keratinocytes with mild 
keratin and pilosebaceous units (Figure 8A), whereas mice 
treated with DMBA followed by no POH treatment (positive 
control) had obvious profuse papillomatous growth with 
complex fibrovascular core, prominent acanthosis and keratin 
perl (Figure 8B). On the other hand, in the free POH treated 
group, a large amount of keratin and marked acanthosis was 
visible as depicted in Figure 8C, while hyperkeratosis, only 
mild acanthosis, and thin but long papillary growth was 
observed in animals treated with POH-PLGA microparticles 
(Figure 8D).
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Figure 3 In vitro cytotoxicity of perillyl alcohol against A253 cell line as revealed by MTT assay.
Notes: MTT assay was performed as described in the Materials and methods section. Data represented here are means of three different experiments ± standard 
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significant upregulation of p53wt and p21/waf1 expression in 
comparison with free form POH (POH-PLGA microparticles 
versus free POH; P , 0.05).
Discussion
Cell-cycle progression in eukaryotes is regulated by several 
key factors that determine whether the cell will re-enter the 
cycle, withdraw from it, or undergo differentiation. A slight 
deviation from the normal course may result in uncontrolled 
proliferation of the cells that eventually form the basis of 
cell transformation. In general, malignant state is preceded 
by several discernible stages, including initiation of DNA 
damage followed by tumor promotion both in vivo and cancer 
cells growing in vitro.
A large number of phytochemicals have been reported 
to prevent or arrest uncontrolled growth of cells through a 
variety of operative mechanisms. Current global focus is 
on natural products as a means to control various types of 
cancers. Some plant-based products possess strong anti-
oxidant properties and have the potential to control or even 
reverse the process of carcinogenesis and emerge as potential 
alternatives to chemotherapeutic anticancer agents.23 How-
ever, before developing such potential phytochemicals as 
prospective therapeutic agents, certain challenges such as 
palatability, poor solubility, and other related problems have 
to be addressed. Some of these can be generally circumvented 
through the use of an appropriate delivery system that has 
potential to modify the pharmacokinetics of the drug and 
facilitate its controlled and even preferential release at the 
desired tumor site.
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time periods, and cell lysates were used to examine the expression of apoptotic molecules. (A) Expression profile of apoptotic factors at 12 hours post-incubation.   
(B) Expression profile of apoptotic factors at 24 hours post-incubation.
Abbreviations: PLGA, poly-lactic glycolic acid; POH, perillyl alcohol.
Western blot analysis
DMBA is generated from incomplete combustion of various 
organic substances. It is cytotoxic, mutagenic, and inflicts 
carcinogenic effects in humans and animal models.21,22 
DMBA induces skin papillomas in animal models by upregu-
lating p53 mutant in cancer cells. As shown in Figure 9, POH-
PLGA microparticles downregulate p53-mutant expression 
significantly when compared with free form of POH. Western 
blot analysis was also performed to assess expression of 
p53wt and p21/waf1. POH-PLGA microparticles showed 
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Figure  6  chemotherapeutic  effect  of  two  different  formulations  of  POh  in 
regression of tumors in treated animals.
Notes:  Percentage  regression  was  calculated  to  analyze  the  most  effective 
formulation of POh. It was assessed by measuring the size with Vernier calipers, and 
tumor volume was calculated as given in the Materials and methods section (POH-
PLgA microparticles versus free form POh; P , 0.001). Sham-PLGA microparticles 
behaved as control.
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POH, a dietary constituent and a mono-terpene isolated 
from cherries, had been used widely as an anticancer agent 
against various types of cancer in animal models.4,24,25 POH is 
known to arrest cells in G0/G1 phase and induce apoptosis.26 
Although POH is a very effective chemotherapeutic agent, its 
anticancer properties have not been explored completely. In 
fact, certain intrinsic properties of POH such as small size, 
poor solubility in aqueous solution, and bioavailability restrict 
attainment of its effective concentration at the targeted site 
and thus limit its application in cancer treatment. Earlier stud-
ies suggest that localized delivery at the targeted site could 
be enhanced significantly by the use of microparticle-based 
drug delivery and eventually can be successfully employed 
in tumor therapy.27,28 It has recently been demonstrated that 
naturally occurring phytochemicals can be encapsulated, 
covalently attached, and adsorbed onto microparticles in order 
to surmount drug-solubility problems.10,29,30 The constituents 
of the microparticle-based delivery system can also facilitate 
co-solubilization of the compound/drug in question. This 
approach has significant implication in cancer therapeu-
tics because more than nearly half of the phytochemicals 
showing anticancer activity have solubility constraints.31 
Nanosize range of the microparticles entails a high surface 
area that not only provides sustained drug release but also 
provides a useful strategy for their functionalization. The 
present study focuses on development and characterization 
of various POH-bearing microparticle formulations and their 
evaluation in chemotherapy against DMBA-induced skin 
papilloma in Swiss albino mice.
The POH-bearing PLGA microparticle formulation 
was characterized for sizing using electron microscopy, 
and its surface charge properties were assessed on the 
basis of ζ-potential. The biophysical properties of the novel 
formulation were also assessed. Further, in vitro anticancer 
efficacy of PLGA based POH formulation was examined 
against human epidermoid cancer cell line (A253). Finally, 
the in vivo therapeutic potential of POH-PLGA microparticle 
formulations was evaluated on the basis of tumor size regres-
sion, survival, histology, and expression profiles of various 
apoptotic molecules.
To optimize the size and loading efficiency of the active 
components, a series of PLGA-based microparticles with 
varying compositions were prepared. The size of the in-
house prepared microparticles was standardized by incor-
porating PLGA of various molecular- masses. Further, the 
entrapment efficiency at various added weight percentage 
values of POH to PLGA was examined. It was found 
that 50%–70% weight of POH to that of PLGA leads to 
entrapment efficiency of around 42.4 ± 3.5 with the size 
of prepared microparticles in the range of 768 ± 215 nm 
(Figure 1A and B). This formulation of POH-PLGA was 
used in subsequent studies.
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Usage of the free form drug does not allow attainment of 
effective concentration unless a large payload is administered, 
which ironically results in many untoward effects. In such 
cases, drug-delivery systems offer help by providing continu-
ous and constant supply of the therapeutics for an extended 
time period. The hydrophobic POH is likely to be physi-
cally dispersed by its encapsulation throughout the matrix 
of PLGA particle. The release kinetics of the entrapped 
drug showed an overall slow and sustained release that was 
likely to be regulated by rate of polymer biodegradation. 
The release kinetics of entrapped drug was determined by 
incubating the drug-bearing microparticles in PBS, pH 7.4 
at 37°C to simulate physiological conditions. The amount of 
released POH was estimated by reverse phase HPLC analysis. 
A linear release of POH accounted for around 22% of the 
total POH entrapped in PLGA microparticles. In concur-
rence with earlier reports, where PLGA with the 50:50 ratio 
of lactic:glycolic acid composition was found to degrade in 
1–2 months,32 the in-house-prepared PLGA microparticles 
acquired steady release and showed 30% release of entrapped 
molecules in a time span of 7 days (Figure 1C).
Both in vitro and in vivo toxicity data revealed that POH-
bearing PLGA microparticles had negligible toxicity when 
compared with free form of the drug and thus assures its 
safety (Figure 2 and Table 1). The cytotoxicity of free POH 
was next examined, and it was found that POH had an IC50 
of 25 µg/mL against A253 human epidermoid cancer cells 
(Figure 3). This concentration was used to analyze differential 
cytotoxicity of free and PLGA microformulation-encapsulated 
POH and their comparative potential in induction of apoptosis 
in epidermoid cancer cell line. Due to faster uptake and sub-
sequent release of the drug by POH-PLGA microparticles, it 
exerts more cytotoxic effect on epidermoid cancer cells than 
its free form (Figure 4). This observation could be explained 
on the premise that application of POH-PLGA microparticles 
delivers a high amount of active drug at the tumor site mainly. 
Further, polymer conjugation of low molecular weight drugs 
alters their biodistribution; enabling their passive targeting 
and reducing access to sites of   toxicity.33 Microparticle-based 
drug formulations entertain a special status in improving the 
efficacy of drug against many types of cancers. Therefore, 
the present study was extended to gain insight in POH-PLGA 
microparticle-mediated modulation of various proteins 
involved in the apoptosis of A253 cells.   Western blot analysis 
was performed to determine levels of various cell cycle and 
apoptosis regulating factors. As evident from Figure 5A, 
incubation of  POH-microparticle formulation with epidermoid 
cancer cells resulted in enhanced expression of p21/waf1 
when compared with free form of POH. The expression of 
another important pro-apoptotic factor Bax was also analyzed 
in A253 cells upon their incubation with POH-microparticle 
formulations. The POH-microparticle formulation up-regulates 
the expression of Bax, thereby enhancing apoptosis induc-
tion in cancer cells (Figure 5A). In the control groups (cells 
treated with sham PLGA microparticles), the expression 
profile of these molecules was not significantly affected 
when compared with POH-PLGA microparticles, suggest-
ing that microparticle-based formulation is effective in 
upregulating p21/waf1 and Bax gene expression. The effect 
of  POH-PLGA microparticles on expression of pro-apoptotic 
molecules was more prominent after 24 hours incubation 
(Figure 5B). Interestingly, the POH-PLGA microparticle was 
Figure  8  Photomicrographs  of  hematoxylin/eosin-stained  sections,  showing: 
(A) normal smooth skin of healthy animals with keratinocytes of only a few cell layers 
thick, mild keratin, and pilosebaceous units; (B) the positive control (DMBA treated 
animals followed by no POH treatment) has profuse papillomatous growth with 
complex fibrovascular core, prominent acanthosis, and keratin perl; (C) treatment 
with free form of POh resulted in large amount of keratin, and marked acanthosis; 
while (D) the treatment with PLGA microsphere encapsulated POH resulted in 
hyperkeratosis, mild acanthosis, and thin but long papillary growth.
Note: Magnification 100×.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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equally successful in downregulating p53-mutant expression 
in A253 cancer cells (data not shown). Of note, both p53 
and/or p21-dependent and -independent pathways have been 
previously reported to be involved in POH-induced cell cycle 
arrest and apoptosis in cancer cells; however, the extent of the 
cell responses varied and can be attributed to the mechanism 
operative in a specific cell type involved and the doses of the 
drug used in the study.34,35
DMBA, a polycyclic aromatic hydrocarbon, is metabolized 
to chemically reactive electrophile and initiate a cascade 
of reaction that eventually results in carcinogenesis by 
covalent interaction(s) with DNA.22 Further investigations 
suggest that it induces skin papilloma in animal models by 
mutagenesis in Ha-ras oncogene.36 Upon topical application 
of POH-PLGA microparticles, 80.8 ± 5.2 regression in tumor 
size was observed after the treatment, whereas free form 
POH showed only 65.1 ± 7.1 regression (Figure 6). Increased 
regression in the POH-PLGA microparticle group could be 
attributed to sustained release of POH. Interestingly, the 
tumor regression results were found to have great correlation 
with survival rate of the treated animals. In case of POH-
PLGA microparticles, survival rate was highest (80%) over 
a period of 13 weeks when compared with survival rate of 
the animals treated with free form POH (40%) (Figure 7). 
Further, histopathological analysis of the skin tissues isolated 
from treated animals was performed and the results clearly 
demonstrated that free form POH had more acanthosis and 
papillary growth than POH-bearing PLGA microformula-
tions (Figure 8). The pro-apoptotic gene p53 regulates the 
balance between cell proliferation and cell death.37,38 It has 
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Figure 9 Effect of different POH-bearing formulations on the expression of different apoptosis-regulating molecules in treated animals.
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been observed that the p53 gene gets mutated in most types 
of the malignancies, including sarcomas. Upon exposure to a 
potent carcinogen, the toxic insult of the cell is generally nul-
lified by a chain of cell cycle regulatory events programmed 
to check the uncontrolled proliferation by a suitable repair 
mechanism.39 The failure to induce expression of functional 
p53wt leads to disregulation of cell cycle arrest or cell death 
and tumor progression. The results of the present study 
showed decreased p53-mutant expression upon   treatment 
with POH-bearing PLGA microparticles. Also, higher 
  efficacy of the microparticle-based formulation of POH can 
be correlated with upregulated expression of p53wt and p21/
waf1 genes (Figure 9).
The survival data further establish higher supremacy of 
POH-PLGA microparticles over its free form. The observed 
higher efficacy of POH-bearing PLGA   microparticle 
formulations can possibly be attributed to the greater 
  bioavailability of POH and its accumulation at the tumor site. 
Finally, it can be inferred that microparticle-based formula-
tions not only overcome the solubility constraints of the poorly 
water soluble POH but also facilitate its release in regulated 
fashion that eventually results in better efficacy of POH in 
terms of tumor regression and survival of treated animals.
Conclusion
Entrapment of POH in PLGA microparticles makes its release 
more sustained, thereby facilitating accumulation of required 
concentration at the target site. As revealed by cytotoxic assay, 
POH-bearing PLGA microparticles showed greater growth 
inhibition of human epidermoid cancer cell line than free form 
POH. Further, higher tumor regression, increased survival, 
histopathological study, and Western blot profiles of various 
cell cycle regulatory proteins clearly suggest that POH-PLGA 
microparticles offer better efficacy than free form POH against 
DMBA-induced skin papillomas in animal models.
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